Drug everolimus shows promise in slowing Children's brain tumors
NCT ID NCT01734512
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested the drug everolimus in 65 children whose low-grade gliomas had come back or worsened. The goal was to see if the drug could stop or slow tumor growth. Children took everolimus pills daily, and doctors tracked tumor changes with MRI scans. The study focused on how many children remained progression-free after 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Everolimus (a drug that blocks a protein called mTOR to slow tumor growth)
What this could lead to
If successful, everolimus could offer a new treatment option to control tumor growth and delay progression in children with low-grade gliomas.
What could go wrong
This is a small, single-arm phase 2 study without a placebo group, so results may not be definitive. The drug may cause side effects like mouth sores, infections, or metabolic changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PILOCYTIC ASTROCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital Oakland
Oakland, California, 94609, United States
-
Children's Hospitals and Clinics of Minneapolis
Minneapolis, Minnesota, 55404, United States
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Johns Hopkins University
Baltimore, Maryland, 21218, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
St. Louis Children's Hospital, Washington University
St Louis, Missouri, 63130, United States
-
The Children's Hospital Of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
University of California, Los Angeles
Los Angeles, California, 90027, United States
-
University of California, San Diego Rady Children's Hospital
San Diego, California, 92123, United States
-
University of California, San Francisco
San Francisco, California, 94158, United States
-
University of Florida
Gainesville, Florida, 32611, United States
-
University of Utah
Salt Lake City, Utah, 84112, United States
-
University of Washington, Seattle
Seattle, Washington, 98195, United States